A Focused Systematic Review of Pharmacological Treatment for Borderline Personality Disorder

@article{HancockJohnson2017AFS,
  title={A Focused Systematic Review of Pharmacological Treatment for Borderline Personality Disorder},
  author={Ella Hancock-Johnson and Chris J Griffiths and Marco M. Picchioni},
  journal={CNS Drugs},
  year={2017},
  volume={31},
  pages={345-356}
}
AbstractBackgroundMedicines are routinely prescribed to treat borderline personality disorder (BPD) despite a relative lack of high-quality evidence and in breach of some treatment guidelines. An earlier Cochrane review of pharmacotherapy in BPD underlined the lack of evidence, encouraged the replication of earlier studies, but also emphasised the pressing need for more randomised placebo-controlled trials, and for those studies to employ broadened inclusion criteria.MethodThe authors searched… 
Pharmacological Treatments for Borderline Personality Disorder: A Systematic Review and Meta-Analysis
TLDR
Low-certainty evidence indicates that anticonvulsants can improve specific symptoms associated with BPD such as anger, aggression, and affective lability but the evidence is mostly limited to single studies.
Pharmacotherapy of borderline personality disorder: replacing confusion with prudent pragmatism
TLDR
Clinicians are either advised to almost completely avoid pharmacotherapy for BPD or use a ‘targeted’ approach, administering specific medications for the specific symptoms of BPD.
Current and emerging medications for borderline personality disorder: is pharmacotherapy alone enough?
TLDR
An individualized, tailored pharmacotherapy for BPD that targets the prominent symptom clusters can improve relevant aspects of the clinical picture, but no medication is indicated to treat the global psychopathology of BPD.
Pharmacotherapy of borderline personality disorder: what has changed over two decades? A retrospective evaluation of clinical practice
TLDR
In inpatient settings, pharmacotherapy is still highly prevalent in the management of BPD, and prescriptions changed between 1996 and 2012, where quetiapine was preferred, older antidepressants and low-potency antipsychotics were avoided.
Off-Label Use of Second-Generation Antipsychotics in Borderline Personality Disorder: A Survey of Italian Psychiatrists.
TLDR
The results reiterate the discrepancy between everyday clinical practice and international recommendations, and show how relevant the literature is in off-label drug prescription.
Evaluation of international guidance for the community treatment of complex emotional needs: A systematic review
TLDR
This systematic review aimed to identify and synthesise recommendations made by different mental health organisations from across the world on community treatment for people with CEN, and identified four main domains, with a total of 27 themes.
Psychological interventions for individuals with a diagnosis of borderline personality disorder in forensic settings: A systematic review
ABSTRACT Borderline Personality Disorder (BPD) is a common diagnosis in forensic settings. Associated difficulties include impulsivity and emotional dysregulation, which can create a vulnerability to
...
1
2
3
...

References

SHOWING 1-10 OF 32 REFERENCES
Pharmacological interventions for borderline personality disorder.
TLDR
The findings were suggestive in supporting the use of second-generation antipsychotics, mood stabilisers, and omega-3 fatty acids, but require replication, since most effect estimates were based on single studies.
Borderline personality disorder: current drug treatments and future prospects
TLDR
Overall, meta-analysis provides little evidence to support the use of antidepressant medication in BPD outside episodes of major depression, but there is evidence for theUse of both mood stabilizers and antipsychotic medications for the treatment of specific aspects of the disorder.
Efficacy and tolerability of duloxetine in the treatment of patients with borderline personality disorder: a pilot study
TLDR
Initial results suggest that duloxetine is an effective and well-tolerated treatment for BPD, with positive effects on somatic symptoms.
The use of psychotropic medication in patients with emotionally unstable personality disorder under the care of UK mental health services.
TLDR
The nature and quality of current prescribing practice for personality disorder across the United Kingdom is characterized as part of a quality improvement program to characterize the nature andquality of psychotropic medication in EUPD.
Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study
TLDR
Individuals treated with olanzapine and placebo showed significant but not statistically different improvements on overall symptoms of borderline personality disorder.
Olanzapine Versus Haloperidol in the Management of Borderline Personality Disorder: A Randomized Double-Blind Trial
TLDR
There seems to be no significant difference between olanzapine and haloperidol regarding the management of mental and behavioral symptoms of patients with BPD.
Evaluation of naltrexone for dissociative symptoms in borderline personality disorder
TLDR
The data provide the first estimate of the pure pharmacological antidissociative efficacy of naltrexone from a rigorously designed trial.
A comparative study on olanzapine and aripiprazole for symptom management in female patients with borderline personality disorder
ABS TRACT: A comparative study on olanzapine and aripiprazole for symptom management in female patients with borderline personality disorder Objective: While Second Generation Antipsychotics (SGAs)
...
1
2
3
4
...